Trial Profile
A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Nov 2021
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 22 Oct 2021 Planned End Date changed from 1 Jun 2019 to 1 Jun 2027.
- 22 Oct 2021 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2025.
- 14 May 2013 Additional lead trial center identified as reported by ClinicalTrials.gov.